Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond.
Barcelona, Spain. In Cancer Biol Med, Sep 2014
However, the cancer genome landscape is composed of relatively few "mountains" [representing the most commonly mutated genes like KRAS, epidermal growth factor (EGFR), and anaplastic lymphoma kinase (ALK)] and a vast number of "hills" (representing low frequency but potentially actionable mutations).
Immunotherapy for Lung Cancer: Has it Finally Arrived?
Calgary, Canada. In Front Oncol, Dec 2013
Despite significant progress in the molecular era now with targeted therapeutics such as EGFR tyrosine kinase inhibitors and ALK fusion protein inhibitors that have significantly improved the outcome of these specific lung cancer subpopulations, the overall 5 year survival for all non-small cell lung cancer (NSCLC) is still <20%.
Comparison of clinical features, molecular alterations, and prognosis in morphological subgroups of lung invasive mucinous adenocarcinoma.
More papers using
Shanghai, China. In Onco Targets Ther, Dec 2013
We investigated differences in clinicopathological characteristics, recurrence-free survival (RFS), overall survival (OS), and a spectrum of well-identified driver-gene mutations, including EGFR, KRAS, HER2, BRAF, ALK, ROS1, and RET, between the two subgroups.
Treatment of eccrine porocarcinoma with metastasis to the parotid gland using intensity-modulated radiation therapy: a case report
In PLoS ONE, 2009
... CA), ER (SP1, prediluted, Ventana Medical Systems, Tucson, AZ), PR (1E2, prediluted, Ventana Medical Systems), EGFR (3C6, prediluted, Ventana Medical Systems), and HER2 (4B5, prediluted, ... Potential use of an anticancer drug gefinitib, an EGFR inhibitor, on allergic airway inflammation.
In PLoS ONE, 2006
... antibody against phospho-IκBα, IκBα, phospho-IKKα/β, IKKα, IKKβ, phospho-p38, p38, phospho-MKK3/6, MKK3, phospho-Akt, Akt, phospho-EGFR and EGFR were purchased from Cell Signaling (MA, USA) ... Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex
In Breast cancer research : BCR, 2003
... used in this study: extracellular signal-regulated kinase 1/2 (ERK1/2), p-ERK1/2, total β-catenin, poly(ADP-ribose)polymerase (PARP), EGFR, p-EGFR (tyrosine [Tyr] 845), and p-Tyr-100 (Cell Signaling Technology, Inc., Danvers, MA, ... Insulin-like growth factor-I inhibits transcriptional responses of transforming growth factor-beta by phosphatidylinositol 3-kinase/Akt-dependent suppression of the activation of Smad3 but not Smad2.
In PLoS ONE, 2002
... (Abcam, ab654), Glut3 (made in Devaskar's lab, UCLA), Glut1 (Abcam, ab15309), IGFR (Cell Signaling, 111A9), EGFR, (Santacruz, sc 03, 1005), Glucose-6-P dehydrogenase (Abcam, ab34436), Protein Kinase C-zeta ... Can correct protein models be identified?
In Molecular Immunology, 2002
... removed with xylene from sections and immunohistochemistry was performed using the FDA-approved in vitro diagnostic EGFR pharm Dx™ (DAKO, Glostrup, Denmark) and HercepTest ... Protein tyrosine phosphorylation influences adhesive junction assembly and follicular organization of cultured thyroid epithelial cells
In British Journal of Cancer, 1996
... -catenin, and p120 (Transduction Laboratories, California, USA), phosphorylated MARCKS (Cell Signaling, Massachusetts, USA), phosphorylated EGFR (Cell Signaling, Massachusetts, USA), and EGFR ...